• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文会议>IEEE International Congress on Big Data >Using clinical data, hypothesis generation tools and PubMed trends to discover the association between diabetic retinopathy and antihypertensive drugs
【24h】

Using clinical data, hypothesis generation tools and PubMed trends to discover the association between diabetic retinopathy and antihypertensive drugs

机译：利用临床数据，假设生成工具和PubMed趋势发现糖尿病性视网膜病变与降压药之间的关联

获取原文
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Diabetic retinopathy (DR) is a leading cause of blindness and common complication of diabetes. Many diabetic patients take antihypertensive drugs to prevent cardiovascular problems, but these drugs may have unintended consequences on eyesight. Six common classes of antihypertensive drug are angiotensin converting enzyme (ACE) inhibitors, alpha blockers, angiotensin receptor blockers (ARBs), β-blockers, calcium channel blockers, and diuretics. Analysis of medical history data might indicate which of these drugs provide safe blood pressure control, and a literature review is often used to guide such analyses. Beyond manual reading of relevant publications, we sought to identify quantitative trends in literature from the biomedical database PubMed to compare with quantitative trends in the clinical data. By recording and analyzing PubMed search results, we found wide variation in the prevalence of each antihypertensive drug in DR literature. Drug classes developed more recently such as ACE inhibitors and ARBs were most prevalent. We also identified instances of change-over-time in publication patterns. We then compared these literature trends to a dataset of 500 diabetic patients from the UT Hamilton Eye Institute. Data for each patient included class of antihypertensive drug, presence and severity of DR. Graphical comparison revealed that older drug classes such as diuretics, calcium channel blockers, and β-blockers were much more prevalent in the clinical data than in the DR and antihypertensive literature. Finally, quantitative analysis of the dataset revealed that patients taking β-blockers were statistically more likely to have DR than patients taking other medications, controlling for presence of hypertension and year of diabetes onset. This finding was concerning given the prevalence of β-blockers in the clinical data. We determined that clinical use of β-blockers should be minimized in diabetic patients to prevent retinal dam- ge.
机译：糖尿病性视网膜病（DR）是糖尿病失明和常见并发症的主要原因。许多糖尿病患者服用降压药来预防心血管疾病，但是这些药物可能会对视力产生意想不到的后果。六种常见的降压药是血管紧张素转换酶（ACE）抑制剂，α受体阻滞剂，血管紧张素受体阻滞剂（ARB），β受体阻滞剂，钙通道阻滞剂和利尿剂。对病史数据的分析可能表明这些药物中的哪些可提供安全的血压控制，并且通常使用文献综述来指导此类分析。除了相关出版物的人工阅读之外，我们还试图从生物医学数据库PubMed中识别文献中的定量趋势，以与临床数据中的定量趋势进行比较。通过记录和分析PubMed搜索结果，我们发现DR文献中每种降压药的患病率差异很大。最近开发的药物类别最为广泛，例如ACE抑制剂和ARB。我们还确定了发布模式中的时间变化实例。然后，我们将这些文献趋势与来自UT Hamilton眼科研究所的500名糖尿病患者的数据集进行了比较。每位患者的数据包括降压药类别，DR的存在和严重程度。图形比较表明，较早的药物种类，例如利尿剂，钙通道阻滞剂和β阻滞剂，在临床数据中比在DR和降压文献中更为普遍。最后，对数据集的定量分析显示，服用β受体阻滞剂的患者在统计学上比服用其他药物的患者更有可能患DR，从而控制了高血压的发生和糖尿病的发作时间。考虑到临床数据中β受体阻滞剂的普遍存在，这一发现令人担忧。我们确定在糖尿病患者中应尽量减少β受体阻滞剂的临床使用，以防止视网膜损伤。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号